

**TRANSMITTAL  
FORM***(to be used for all correspondence after initial filing)***Application Number**

10/618,444

**Filing Date**

July 11, 2003

**First Named Inventor**

Julie K. Andersen

**Group Art Unit**

1642

**Examiner Name**

Unassigned

**Total Number of Pages in This Submission****Attorney Docket Number**

314-300710US

**ENCLOSURES (check all that apply)**

- ☐ Fee Transmittal Form  
☐ Fee Attached
- ☐ Amendment / Response  
☐ After Final  
☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/  
Incomplete Application
- ☐ Response to Missing  
Parts under 37 CFR  
1.52 or 1.53

- ☐ Assignment Papers  
(for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69)  
and Accompanying Petition
- ☐ Petition to Convert to a  
Provisional Application
- ☐ Power of Attorney, Revocation  
Change of Correspondence  
Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication  
to Group
- ☐ Appeal Communication to Board  
of Appeals and Interferences
- ☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s)  
(please identify below):

PTO Form 1449  
44 Cited References  
receipt acknowledgment  
postcard

**Authorization to Charge Deposit Account**

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

**Remarks****SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT****Firm  
or  
Individual name**

Tom Hunter, Reg. No. 38,498,

Quine Intellectual Property Law Group P.C.

**Signature****Date**

December 8, 2004

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231 on this date: December 8, 2004

**Typed or printed name**

Chianti Appling

**Signature****Date**

12/8/04



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on December 8, 2004

QWINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Chianti [Signature]

Attorney Docket No. 314-300710US  
Client Ref. No. B1-335

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Julie K. Andersen, et al.

Application No.: 10/618,444

Filed: July 11, 2003

For: IRON SEQUESTRATION OR  
ELIMINATION TO REDUCE  
NEURODEGENERATION OR  
PARKINSONS DISEASE  
PROGRESSION

Confirmation No.

Examiner: Unassigned

Art Unit: 1642

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR § 1.97 and  
§ 1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Tom Hunter', with a long horizontal flourish extending to the right.


Tom Hunter, J.D., Ph.D.  
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
P.O. BOX 458  
Alameda, CA 94501  
(510) 337-7871  
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/618,444
Filing Date	July 11, 2003
First Named Inventor	Julie K. Andersen
Group Art Unit	1642
Examiner Name	Unassigned
Attorney Docket Number	314-300710US
Date Submitted	December 8, 2004

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	5,206,226		Sabin	4/27/1993	
	2	5,906,996		Murphy	5/25/1999	
	3	6,417,177		Nelson	7/9/2002	
	4	6,573,257		Malfroy-Camine et al.	7/3/2003	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	5	Adams and Odunze (1991) <i>Free Radic Biol. Med.</i> 10, 161-169	
	6	Andersen, J.K. (2001) Pp. 11-25 In: <i>Ageing Vulnerability: Causes and Interventions</i> , Novartis	
	7	Foundation Symposium 235, John Wiley and Sons, Inc	
	8	Beal (1992) <i>Ann. Neurol.</i> 31: 119-130	
	9	Ben-Shachar <i>et al.</i> (1991) <i>J. Neurochem.</i> , 56(4): 1441-1444	
	10	Berg <i>et al.</i> (2001) <i>J. Neurochem.</i> 79: 225-236	
	11	Bush and Masters (2001) <i>Science</i> 292: 2251-2252	
	12	Castellani <i>et al.</i> (2000) <i>Proc. Natl. Acad. Sci. USA</i> 98: 14669-14674	
	13	Cherny <i>et al.</i> (2001) <i>Neuron</i> 30: 665-676	
	14	Connor <i>et al.</i> (1995) <i>J. Neurochem.</i> 65: 717-724	
	15	Connor <i>et al.</i> (2001) <i>Pediatr. Neurol.</i> 25: 118-129	
	16	Cozzi <i>et al.</i> (2000) <i>J. Biol. Chem.</i> 275: 25122-25129	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>10/618,444</b>
	Filing Date	<b>July 11, 2003</b>
	First Named Inventor	<b>Julie K. Andersen</b>
	Group Art Unit	<b>1642</b>
	Examiner Name	<b>Unassigned</b>
	Attorney Docket Number	<b>314-300710US</b>
	Date Submitted	<b>December 8, 2004</b>

17	Curtis <i>et al.</i> (2001) <i>Nat. Genet.</i> 28: 350-354	
18	Dexter <i>et al.</i> (1987) <i>Lancet</i> 21: 1219-1220	
19	Dexter <i>et al.</i> (1989) <i>J. Neurochem.</i> 52: 1830-1836	
20	Du <i>et al.</i> (2001) <i>Proc. Natl. Acad. Sci. USA</i> 98: 14669-14674	
21	Galvani <i>et al.</i> (1995) <i>Toxic In Vitro</i> , 9(4): 365-368	
22	Gassen <i>et al.</i> (1997) <i>Pharmacol., &amp; Toxicol.</i> , 80: 159-166	
23	Gerlach <i>et al.</i> (1994) <i>J. Neurochem.</i> 63:793-807	
24	Griffiths <i>et al.</i> (1999) <i>Brain</i> 122: 667-673	
25	Gutteridge (1992) <i>Ann. Neurol.</i> 32: S16-S21	
26	Han <i>et al.</i> (2000) <i>Cell Mol. Biol.</i> 46: 517-528	
27	Harrison and Arosio (1996) <i>Biochim. Biophys. Acta</i> 1275: 161-203	
28	Huang <i>et al.</i> (1999) <i>J. Biol. Chem.</i> 274: 37111-37116	
29	Kato, <i>et al.</i> (2001) <i>Am. J. Hum. Genet.</i> 69: 191-197	
30	Kaur and Andersen (2002) <i>Aging Cell.</i> 1(1): 17-21	
30	Kaur and Andersen (2004) <i>Ageing Res Rev.</i> 3(3): 327-43	
32	Kaur <i>et al.</i> (2003) <i>Neuron.</i> 37(6): 889-890.	
33	Kidani <i>et al.</i> (1974) <i>Jap. Analyst</i> 23, 1375-1378	
34	Lan and Jiang (1997) <i>J. Neural Transm.</i> 104: 649-660	
35	Marciani <i>et al.</i> (1991) <i>Haematologica</i> 76: 131-134	
36	Orino <i>et al.</i> (2001) <i>Biochem. J.</i> 357: 241-247	
37	Porter and Huehns (1989) <i>Baillieres Clin. Haematol.</i> 2: 459-474	
38	Sofic <i>et al.</i> (1988) <i>J. Neural. Transm.</i> 74: 199-205	
39	Sofic <i>et al.</i> (1991) <i>J. Neurochem.</i> 56: 978-982	
40	Thompson <i>et al.</i> (2001) <i>Brain Res. Bull.</i> 55: 155-164	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>10/618,444</b>
	Filing Date	<b>July 11, 2003</b>
	First Named Inventor	<b>Julie K. Andersen</b>
	Group Art Unit	<b>1642</b>
	Examiner Name	<b>Unassigned</b>
	Attorney Docket Number	<b>314-300710US</b>
	Date Submitted	<b>December 8, 2004</b>

	41	Yantiri and Andersen (1999) <i>IUBMB Life</i> 48: 1-3	
	42	Yassin, <i>et al.</i> (2000) <i>J. Neurol. Sci.</i> 173: 40-44	
	43	Yoshida <i>et al.</i> (2001) <i>J. Synchrotron Radiat.</i> 8: 998-1000	
	44	Youdim <i>et al.</i> (1993) <i>Mov. Dis.</i> 8: 1-12	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.